In melanoma treatment, immunotolerance induced by MUC1 vaccination was reversed by anti-PD-L1 antibodies, a process involving an increased CD80/PD-L1 ratio, promotion of dendritic cell maturation, activation of Th1 and Tc1 cells, and inhibition of Treg cells (115). This evidence concerns the gene MUC1 and melanoma.